Pacira BioSciences (PCRX) Short-term Investments (2011 - 2026)

Pacira BioSciences' Short-term Investments history runs 16 years deep, the most recent figure standing at $57.9 million for Q1 2026.

• In Q1 2026, Short-term Investments fell 72.44% year-over-year to $57.9 million; the TTM figure through Mar 2026 stood at $57.9 million (down 72.44% YoY), while the FY2025 annual figure was $79.9 million, down 61.57% from the prior year.
• Short-term Investments was $57.9 million for Q1 2026 at Pacira BioSciences, down from $79.9 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $225.4 million in Q1 2022 to a low of $57.9 million in Q1 2026.
• Historically, Short-term Investments has averaged $156.7 million across 5 years, with a median of $145.4 million in 2025.
• The sharpest annual moves came in 2022 and 2026: Short-term Investments surged 160.5% in 2022, then plunged 72.44% in 2026.
• A 5-year view of Short-term Investments shows it stood at $184.5 million in 2022, then tumbled by 32.1% to $125.3 million in 2023, then soared by 65.9% to $207.8 million in 2024, then tumbled by 61.57% to $79.9 million in 2025, then slipped by 27.55% to $57.9 million in 2026.
• The last three Short-term Investments figures came in at $57.9 million (Q1 2026), $79.9 million (Q4 2025), and $98.7 million (Q3 2025), per Business Quant data.